267 related articles for article (PubMed ID: 11895895)
21. A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma.
Advani R; Peethambaram P; Lum BL; Fisher GA; Hartmann L; Long HJ; Halsey J; Holmlund JT; Dorr A; Sikic BI
Cancer; 2004 Jan; 100(2):321-6. PubMed ID: 14716767
[TBL] [Abstract][Full Text] [Related]
22. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors.
Marshall J; Chen H; Yang D; Figueira M; Bouker KB; Ling Y; Lippman M; Frankel SR; Hayes DF
Ann Oncol; 2004 Aug; 15(8):1274-83. PubMed ID: 15277270
[TBL] [Abstract][Full Text] [Related]
23. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
Sosman JA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Weiss GR; Isaacs RE; Margolin KA; Fisher RI; Ernest ML; Mier J; Oleksowicz L; Eckhardt JR; Levitt D; Doroshow JH
Clin Cancer Res; 1997 Jan; 3(1):39-46. PubMed ID: 9815535
[TBL] [Abstract][Full Text] [Related]
24. Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies.
Galatin PS; Advani RH; Fisher GA; Francisco B; Julian T; Losa R; Sierra MI; Sikic BI
Invest New Drugs; 2011 Oct; 29(5):971-7. PubMed ID: 20349264
[TBL] [Abstract][Full Text] [Related]
25. Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer.
Morris MJ; Cordon-Cardo C; Kelly WK; Slovin SF; Siedlecki K; Regan KP; DiPaola RS; Rafi M; Rosen N; Scher HI
Appl Immunohistochem Mol Morphol; 2005 Mar; 13(1):6-13. PubMed ID: 15722787
[TBL] [Abstract][Full Text] [Related]
26. A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumors.
Goel S; Desai K; Bulgaru A; Fields A; Goldberg G; Agrawal S; Martin R; Grindel M; Mani S
Clin Cancer Res; 2003 Sep; 9(11):4069-76. PubMed ID: 14519628
[TBL] [Abstract][Full Text] [Related]
27. Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia.
Dai G; Chan KK; Liu S; Hoyt D; Whitman S; Klisovic M; Shen T; Caligiuri MA; Byrd J; Grever M; Marcucci G
Clin Cancer Res; 2005 Apr; 11(8):2998-3008. PubMed ID: 15837754
[TBL] [Abstract][Full Text] [Related]
28. Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors.
Tanioka M; Nokihara H; Yamamoto N; Yamada Y; Yamada K; Goto Y; Fujimoto T; Sekiguchi R; Uenaka K; Callies S; Tamura T
Cancer Chemother Pharmacol; 2011 Aug; 68(2):505-11. PubMed ID: 21079959
[TBL] [Abstract][Full Text] [Related]
29. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer.
Rudin CM; Otterson GA; Mauer AM; Villalona-Calero MA; Tomek R; Prange B; George CM; Szeto L; Vokes EE
Ann Oncol; 2002 Apr; 13(4):539-45. PubMed ID: 12056703
[TBL] [Abstract][Full Text] [Related]
30. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells.
Tauchi T; Sumi M; Nakajima A; Sashida G; Shimamoto T; Ohyashiki K
Clin Cancer Res; 2003 Sep; 9(11):4267-73. PubMed ID: 14519654
[TBL] [Abstract][Full Text] [Related]
31. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
[TBL] [Abstract][Full Text] [Related]
32. A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients.
Grem JL; Harold N; Keith B; Chen AP; Kao V; Takimoto CH; Hamilton JM; Pang J; Pace M; Jasser GB; Quinn MG; Monahan BP
Clin Cancer Res; 2002 Jul; 8(7):2149-56. PubMed ID: 12114415
[TBL] [Abstract][Full Text] [Related]
33. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
Hidalgo M; Buckner JC; Erlichman C; Pollack MS; Boni JP; Dukart G; Marshall B; Speicher L; Moore L; Rowinsky EK
Clin Cancer Res; 2006 Oct; 12(19):5755-63. PubMed ID: 17020981
[TBL] [Abstract][Full Text] [Related]
34. Trabedersen, a TGFbeta2-specific antisense oligonucleotide for the treatment of malignant gliomas and other tumors overexpressing TGFbeta2.
Vallières L
IDrugs; 2009 Jul; 12(7):445-53. PubMed ID: 19579166
[TBL] [Abstract][Full Text] [Related]
35. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer.
Tolcher AW; Chi K; Kuhn J; Gleave M; Patnaik A; Takimoto C; Schwartz G; Thompson I; Berg K; D'Aloisio S; Murray N; Frankel SR; Izbicka E; Rowinsky E
Clin Cancer Res; 2005 May; 11(10):3854-61. PubMed ID: 15897586
[TBL] [Abstract][Full Text] [Related]
36. Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.
Moulder SL; Symmans WF; Booser DJ; Madden TL; Lipsanen C; Yuan L; Brewster AM; Cristofanilli M; Hunt KK; Buchholz TA; Zwiebel J; Valero V; Hortobagyi GN; Esteva FJ
Clin Cancer Res; 2008 Dec; 14(23):7909-16. PubMed ID: 19047121
[TBL] [Abstract][Full Text] [Related]
37. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.
Robertson MJ; Mier JW; Logan T; Atkins M; Koon H; Koch KM; Kathman S; Pandite LN; Oei C; Kirby LC; Jewell RC; Bell WN; Thurmond LM; Weisenbach J; Roberts S; Dar MM
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4265-73. PubMed ID: 16857801
[TBL] [Abstract][Full Text] [Related]
38. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
Mita MM; Mita AC; Chu QS; Rowinsky EK; Fetterly GJ; Goldston M; Patnaik A; Mathews L; Ricart AD; Mays T; Knowles H; Rivera VM; Kreisberg J; Bedrosian CL; Tolcher AW
J Clin Oncol; 2008 Jan; 26(3):361-7. PubMed ID: 18202410
[TBL] [Abstract][Full Text] [Related]
39. Modulation of the activity of Bcl-2 in Waldenstrom's macroglobulinemia using antisense oligonucleotides.
Nichols GL; Stein CA
Semin Oncol; 2003 Apr; 30(2):297-9. PubMed ID: 12720156
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts.
Lopes de Menezes DE; Mayer LD
Cancer Chemother Pharmacol; 2002 Jan; 49(1):57-68. PubMed ID: 11855753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]